TY - JOUR
T1 - Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826
AU - Castellino, Sharon M.
AU - Li, Hongli
AU - Herrera, Alex F.
AU - LeBlanc, Michael
AU - Parsons, Susan K.
AU - Unger, Joseph M.
AU - Punnett, Angela
AU - Hodgson, David
AU - Keller, Frank G.
AU - Drachtman, Richard A.
AU - Lamble, Adam
AU - Forlenza, Christopher J.
AU - Doan, Andrew
AU - Rutherford, Sarah C.
AU - Evens, Andrew M.
AU - Little, Richard F.
AU - Smith, Malcolm A.
AU - Hoppe, Bradford S.
AU - Song, Joo Y.
AU - Smith, Sonali M.
AU - Friedberg, Jonathan W.
AU - Kelly, Kara M.
N1 - Publisher Copyright:
© 2026 by American Society of Clinical Oncology
PY - 2026/2/20
Y1 - 2026/2/20
N2 - We present a subset analysis on the adolescent cohort of the S1826 randomized phase three trial, comparing nivolumab, doxorubicin, vinblastine, dacarbazine (N-AVD) to brentuximab vedotin-AVD (BV-AVD) in newly diagnosed advanced-stage (AS, stages III and IV) classic Hodgkin lymphoma (cHL). Among 994 patients enrolled, 24% (n = 240) were age 12-17 years. The 3-year progression-free survival (PFS) was significantly higher in the N-AVD group (93% [95% CI, 87 to 96]) compared with the BV-AVD group (82% [95% CI, 73 to 88]; hazard ratio, 0.37 [95% CI, 0.17 to 0.80]). One N-AVD and two BV-AVD patients received protocol-specified residual site radiotherapy (RT). Rates of febrile neutropenia and sepsis were low in both groups. Severe immune-related adverse events were infrequent, although thyroid dysfunction was seen in 7% with N-AVD. Sensory neuropathy (grade ≥2) was more frequent with BV-AVD (14% v 7%) by clinician report. Although premature discontinuation of therapy was reported in 12 N-AVD patients and four BV-AVD patients, no PFS events were noted in the N-AVD group. Patient-reported outcomes indicated less toxicity with N-AVD. N-AVD demonstrated high 3-year PFS in adolescents with AS cHL, with minimal RT use. S1826 exemplifies the benefits of harmonized clinical trial protocols, resulting in timely access to novel agents for adolescents.
AB - We present a subset analysis on the adolescent cohort of the S1826 randomized phase three trial, comparing nivolumab, doxorubicin, vinblastine, dacarbazine (N-AVD) to brentuximab vedotin-AVD (BV-AVD) in newly diagnosed advanced-stage (AS, stages III and IV) classic Hodgkin lymphoma (cHL). Among 994 patients enrolled, 24% (n = 240) were age 12-17 years. The 3-year progression-free survival (PFS) was significantly higher in the N-AVD group (93% [95% CI, 87 to 96]) compared with the BV-AVD group (82% [95% CI, 73 to 88]; hazard ratio, 0.37 [95% CI, 0.17 to 0.80]). One N-AVD and two BV-AVD patients received protocol-specified residual site radiotherapy (RT). Rates of febrile neutropenia and sepsis were low in both groups. Severe immune-related adverse events were infrequent, although thyroid dysfunction was seen in 7% with N-AVD. Sensory neuropathy (grade ≥2) was more frequent with BV-AVD (14% v 7%) by clinician report. Although premature discontinuation of therapy was reported in 12 N-AVD patients and four BV-AVD patients, no PFS events were noted in the N-AVD group. Patient-reported outcomes indicated less toxicity with N-AVD. N-AVD demonstrated high 3-year PFS in adolescents with AS cHL, with minimal RT use. S1826 exemplifies the benefits of harmonized clinical trial protocols, resulting in timely access to novel agents for adolescents.
UR - https://www.scopus.com/pages/publications/105028823302
U2 - 10.1200/JCO-25-00203
DO - 10.1200/JCO-25-00203
M3 - Article
C2 - 41512237
AN - SCOPUS:105028823302
SN - 0732-183X
VL - 44
SP - 449
EP - 454
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 6
ER -